Cancer Patients and Targeted Therapy During COVID-19 Pandemic: A Descriptive Case Series Study

Overview

Journal Clin Case Rep

Date 2022 Oct 21

PMID 36267821

Authors

Kasra Khodadadi

Minoosh Moghimi

Reza Mansouri

Affiliations

Soon will be listed here.

Abstract

To evaluate the effectiveness of targeted therapy on preventing or treating COVID-19, in this study, we want to share our experience about 14 patients (nine women, five men; average age, 59 years) who were treated with targeted therapy due to their underlying malignant disorders in our center.

Citing Articles

Cancer patients and targeted therapy during COVID-19 pandemic: A descriptive case series study.

Khodadadi K, Moghimi M, Mansouri R Clin Case Rep. 2022; 10(10):e6392.

PMID: 36267821 PMC: 9576967. DOI: 10.1002/ccr3.6392.

References

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R . Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31(7):894-901. PMC: 7270947. DOI: 10.1016/j.annonc.2020.03.296. View

Devaraj N . Antibiotic Resistance: A Real Menace. Oman Med J. 2017; 32(6):531. PMC: 5702986. DOI: 10.5001/omj.2017.102. View

Devaraj N . 'A recurrent cutaneous eruption'. BMJ Case Rep. 2019; 12(2). PMC: 6366803. DOI: 10.1136/bcr-2018-228355. View

OBrien S, Furman R, Coutre S, Flinn I, Burger J, Blum K . Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018; 131(17):1910-1919. PMC: 5921964. DOI: 10.1182/blood-2017-10-810044. View

Yang L, Keating G . Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012; 72(16):2117-27. DOI: 10.2165/11209340-000000000-00000. View

Byrd J, Brown J, OBrien S, Barrientos J, Kay N, Reddy N . Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213-23. PMC: 4134521. DOI: 10.1056/NEJMoa1400376. View

Lin A, Cuttica M, Ison M, Gordon L . Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review. EJHaem. 2020; 1(2):596-600. PMC: 7537222. DOI: 10.1002/jha2.98. View

Khodadadi K, Moghimi M, Mansouri R . Cancer patients and targeted therapy during COVID-19 pandemic: A descriptive case series study. Clin Case Rep. 2022; 10(10):e6392. PMC: 9576967. DOI: 10.1002/ccr3.6392. View

Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D . COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020; 20(4):400-402. PMC: 7158903. DOI: 10.1016/S1473-3099(20)30132-8. View

10.

Gabhann J, Hams E, Smith S, Wynne C, Byrne J, Brennan K . Btk regulates macrophage polarization in response to lipopolysaccharide. PLoS One. 2014; 9(1):e85834. PMC: 3897530. DOI: 10.1371/journal.pone.0085834. View

11.

Erickson J, Gilchuk P, Hastings A, Tollefson S, Johnson M, Downing M . Viral acute lower respiratory infections impair CD8+ T cells through PD-1. J Clin Invest. 2012; 122(8):2967-82. PMC: 3408742. DOI: 10.1172/JCI62860. View

12.

Robilotti E, Babady N, Mead P, Rolling T, Perez-Johnston R, Bernardes M . Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020; 26(8):1218-1223. PMC: 7785283. DOI: 10.1038/s41591-020-0979-0. View

13.

Roschewski M, Lionakis M, Sharman J, Roswarski J, Goy A, Monticelli M . Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020; 5(48). PMC: 7274761. DOI: 10.1126/sciimmunol.abd0110. View

14.

Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J . Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv119-iv142. DOI: 10.1093/annonc/mdx225. View

15.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani P . Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14):1428-1439. PMC: 6075855. DOI: 10.1200/JCO.2017.76.0793. View

16.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

17.

Di Giacomo A, Gambale E, Monterisi S, Valente M, Maio M . SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome. Eur J Cancer. 2020; 133:1-3. PMC: 7196405. DOI: 10.1016/j.ejca.2020.04.026. View

18.

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

19.

Souza I, Fernandes I, Taranto P, Buzaid A, Schvartsman G . Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic. Eur J Cancer. 2020; 135:147-149. PMC: 7298497. DOI: 10.1016/j.ejca.2020.06.004. View

20.

Treon S, Castillo J, Skarbnik A, Soumerai J, Ghobrial I, Guerrera M . The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020; 135(21):1912-1915. PMC: 7243149. DOI: 10.1182/blood.2020006288. View